What science can do足球外围网

Annual Report and Form 20-F
Information 2018
体育外围下注

01

体育外围下注

This Annual Report quick-阅读 provides top-level 资讯rmation on our business and the progress we have made in 2018 in pushing the boundaries of science to deliver life-changing medicines and demonstrating what science can do.



Science can


Science can


Science can


Science can


Science can


02

体育外围下注


In 2018, under the leadership of Pascal Soriot, and together with the entire talented AstraZeneca 团队, we delivered on our promise and returned a reinvigorated AstraZeneca to 产品介绍 Sales growth. We succeeded because we have been true to our Value of following the science. We also succeeded because we put patients first.

Leif Johansson, Chairman

I am pleased to report that, in 2018, after the previous six years in which revenues had fallen by 更多 than one third, we turned the corner and returned to 产品介绍 Sales growth, driven by a new generation of medicines from our therapy areas.

Pascal Soriot, Chief Executive Officer

03

体育外围下注

2018 marked our return to 产品介绍 Sales growth with strong performance from Growth Platforms and New Medicines 更多 than offsetting the continued impact from patent expiries.


足球外围网


Total Revenue*
足球外围网

$22.1bn足球外围网


Net cash flow from operating activities
Down 27% at actual rate of exchange to $2,618 million




足球外围网

$2.6bn足球外围网

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

*Total Revenue consists of Product Sales and Externalisation Revenue.

 

足球外围网


Reported operating profit
Down 8% at actual rate of exchange to $3,387 million (down 7% at CER)
足球外围网

$3.4bn足球外围网


Core operating profit
Down 17% at actual rate of exchange to $5,672 million (down 17% at CER)
足球外围网

$5.7bn足球外围网

足球外围网


Reported EPS
Down 28% at actual rate of exchange to $1.70 (down 29% at CER)
足球外围网

$1.70足球外围网


Core EPS
Down 19% at actual rate of exchange to $3.46 (down 19% at CER)
足球外围网

$3.46足球外围网



04

体育外围下注

We are a global science-led business delivering medicines to patients through innovative science and excellence in development and commercialisation.


体育外围下注


Total Product Sales
体育外围下注

$21,049m体育外围下注

2017: $20,152m
2016: $21,319m
足球外围网


体育外围下注



体育外围下注




体育外围下注


足球外围网

足球外围网

足球外围网

足球外围网

足球外围网

足球外围网


体育外围下注



体育外围下注

Broadening access to healthcare

 



体育外围下注

Furthering ethics and transparency

 



体育外围下注

Protecting the environment

 




体育外围下注



体育外围下注

$0.90足球外围网

Pence: 68.4
SEK: 7.92
Payment date: 10 September 2018
足球外围网


体育外围下注

$1.90足球外围网

Pence:146.8
SEK: 17.46
Payment date: 27 March 2019
足球外围网


体育外围下注

$2.80足球外围网

Pence: 215.2
SEK: 25.38

足球外围网


05

体育外围下注

We announced our strategy for returning to growth in 2013. The first phase in our journey was focused on rebuilding our pipeline. The second stage was crucial as we drove our Growth Platforms forward, continued to launch new medicines and made them available to patients. We returned to Product Sales growth in 2018 and, as we look ahead to 2020 and beyond, continued investment in our product launches and pipeline will keep us on track to deliver sustainable growth in line with our targets.

We are a ‘pure-play’, global, science-led pharmaceutical company. We are focused on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of unmet medical need in three main therapy areas: Oncology; Cardiovascular, Renal and Metabolism (CVRM); and Respiratory. In 2018, our strategic priorities were focused under the three pillars listed below.



2018 Highlights


2018 Highlights


2018 Highlights


体育外围下注